JNJ

Procter & Gamble Appears Overvalued

by

Image Shown: Shares of Procter & Gamble have been on an epic run since mid-2018, and we think shares have gotten ahead of themselves here. By Callum Turcan Consumer staples giant Procter & Gamble (PG) is a solid company that generates sizable and consistent free cash flows. However, in our view, shares of PG have gotten way ahead of themselves due to a “flight to quality” that has seen the market bid up P&G’s share price from the low $70s in April 2018 to almost $120 as of this writing. Shares of PG now yield 2.5% as of this writing and trade well above the top end of our fair value estimate range of $101 per share. Please note P&G … Read more

Johnson & Johnson Announces New Test Results That Reveal No Traces of Asbestos in Johnson Baby Powder Products

by

Image Source: Johnson & Johnson – February 2019 CAGNY IR Presentation By Callum Turcan A holding in both our Dividend Growth Newsletter and Best Ideas Newsletter portfolios, shares of Johnson & Johnson (JNJ) have been on a wild ride of late over dueling narratives regarding the firm’s potential legal liabilities. In particular, liabilities concerning its talc-based Johnson Baby Powder product. On October 18, Johnson & Johnson announced it was voluntarily recalling “a single lot” of its Johnson Baby Powder product (equal to around 33,000 bottles) after the US FDA found sub-traces of chrysotile asbestos in a single bottle (less than 0.00002%). At the time, Johnson & Johnson vigorously defended its baby care brand and said that its Johnson Baby Powder … Read more

Johnson & Johnson’s Talc Problems Hit Another Bump

by

Image Shown: Johnson & Johnson’s embattled ‘Baby Care’ segment performed poorly during the third quarter of 2019. Image Source: Johnson & Johnson – IR Presentation. By Callum Turcan Johnson & Johnson (JNJ) was back in the news Friday October 18 when the company announced it was voluntarily recalling “a single lot” of its embattled Johnson’s Baby Powder product in the US due to alleged asbestos contamination risks. The US Food and Drug Administration tested a single bottle from this lot, according to Johnson & Johnson, with the federal regulator noting that sub-trace levels (no greater than 0.00002%) of chrysotile asbestos had been detected in the bottle. Johnson & Johnson plans to vigorously contest these allegations and maintains that its talc … Read more

Johnson & Johnson Raises Full-Year Guidance Yet Again

by

Image Shown: Shares of Johnson & Johnson climbed higher on October 15 after reporting a nice third quarter earnings report and raising guidance for the full year. By Callum Turcan On October 15, Best Ideas Newsletter and Dividend Growth Newsletter holding Johnson & Johnson (JNJ) reported third-quarter 2019 earnings that were positively received by the market. The healthcare giant once again boosted full-year non-GAAP sales and EPS guidance, which we appreciate, on the back of solid performance at its ‘Pharmaceuticals’ and ‘Medical Devices’ segments. Please note that Johnson & Johnson had already raised its guidance for 2019 twice before this latest increase, which we covered in this July 2019 piece here and this April 2019 piece here. During the third … Read more

Economic Commentary: Robots, Value Trap, and Politics on the Markets

by

Tickerized for stocks in the DIA. Valuentum sat down for the latest installment of its periodic economic commentary, and the team tackled a wide array of topics, from robots on Wall Street, to President of Investment Research Brian Nelson’s new book Value Trap, to political influence on the markets and boyond. Let’s set the stage with a prompt from a recent Bloomberg article, “The Master of Robots…Coming for Wall Street:” “The problem is, computer-powered strategies are struggling to live up to the hype, with a Eurekahedge index of AI hedge funds lagging peers in recent years. That spells opportunity for the likes of Lopez de Prado with his outfit True Positive Technologies — a dig at the erroneous conclusions derived … Read more

ICYMI: Interview with Valuentum’s President Brian M. Nelson, CFA

by

Catch up with Valuentum’s President Brian M. Nelson, CFA in a recent interview with dividend growth investor Arne Magnus Lorentzen Ulland of the blog stockles. By Brian Nelson, CFA Recently, I was interviewed by Arne Magnus Lorentzen Ulland of the blog stockles. Arne is a dividend growth investor like many of you, and I sincerely hope you enjoy the interview he put together. I’m very grateful for his interest. His questions were fantastic. We discuss why and how I incorporate independence and integrity into the service at Valuentum. We go into detail regarding why Valuentum views stocks the way it does, and how Valuentum combines enterprise valuation and the information contained in prices in its stock-selection process. I discuss the pitfalls … Read more

Economic Commentary: Apple $225+, Brokers Tumble, Auto Sales Look Tired

by

“Though all signs point to increased volatility, we maintain our view that we’re well-positioned in the newsletter portfolios, and the ideas highlighted in the Exclusive publication consider the backdrop economic conditions we closely monitor.” — Brian Nelson, CFA There has been plenty of news in the markets this week, with the Dow Jones Industrial Average (DIA) experiencing significant declines only to bounce back a bit. From where we stand, the markets look vulnerable technically, but that doesn’t mean we’re looking to change anything in the newsletter portfolios. We have some dry powder in the form of a ~10% cash weighting in the Best Ideas Newsletter portfolio and Dividend Growth Newsletter portfolio. The disappointing September ADP jobs report added to lower-than-expected ISM (Institute … Read more

Zimmer Biomet’s Near-Term Outlook Is Less Rosy Than Management Would Have You Believe

by

Shares of Zimmer Biomet are trading on lofty expectations and investors may be in for a shock should Zimmer Biomet continue to underperform during the second half of 2019. Foreign currency headwinds continue to grow as seen through the strength of the US Dollar Index during the third quarter of 2019. We like Zimmer Biomet’s deleveraging activities but think its share price has gotten ahead of itself given these rising headwinds, lack of top line growth, and deteriorating net operating cash flows. We are staying away from Zimmer Biomet. By Callum Turcan Zimmer Biomet (ZBH) makes medical devices and shares of ZBH yield 0.7% as of this writing. The company as it stands today was created through Zimmer Holdings acquiring … Read more

Economic Roundtable: “Value” Versus “Growth” Rotation

by

Tickerized for the DIA. “This kind of trading activity could be setting the stage for a big quant fund blow up, if the kind of leverage it takes to move the markets to this magnitude was applied. All it may take is for the B/M “value” factor to continue to suffer in the coming 12-18 months–it’s possible we could see a few quant firms go belly up. My guess is that market participants are paying very close attention to this activity, and if they “smell blood,” things could get ugly.” – Brian Nelson, CFA Earlier this week, the markets experienced significant internal “rotation,” as cyclicals and “value” stocks materially outperformed their defensive and “growth” counterparts, all the while the broader … Read more

Triple-A Rated J&J’s Opioid Liabilities Likely More Than Priced In

by

  Image Source: J&J Shares of J&J have settled into the high-$120s at the time of this writing, well below our ~$150 fair value estimate. We’re going to stick with J&J in both the Dividend Growth Newsletter portfolio and Best Ideas Newsletter portfolio at this time. By Callum Turcan and Brian Nelson, CFA On August 26, an Oklahoma judge ruled that Johnson & Johnson (JNJ) had to pay $572 million to the state over its role in the opioid crisis in America. In particular, District Judge Thad Balkman noted that “Johnson & Johnson’s misleading marketing and promotion of opioids created a nuisance” that compromised the health of thousands in Oklahoma. Johnson & Johnson and its Janssen subsidiary will contest the … Read more